Haleon (HLN) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $44.79B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | GB | CEO | Brian James McNamara |
| IPO Date | 2022-07-25 | CAGR | 4.48% |
| Employees | 24,535 | Website | www.haleon.com |
| Div. Yield | 1.67% | Payout Ratio | 37% |
| Buy Back Yield | 2.24% | Total Yield | 3.91% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $40.18B | P/E | 18.96 | Forward P/E | 16.34 | PEG | -4.62 |
| P/S | 3.35 | P/B | 2.31 | P/CF | 25.21 | P/FCF | 31.5 |
| Sales | $26.13B | Sales 1Y | 14.45% | Sales 3Y | — | Sales 5Y | — |
| EPS | $0.54 | EPS 1Y | 20.5% | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 2.31% | EPS QoQ | -10.53% | Sales QoQ Avg | 13.11% | EPS QoQ Avg | 13.23% |
| Gross Margin | 64.77% | Operating Margin | 21.87% | Profit Margin | 15.11% | ROCE | 8.71% |
| ROA | 5% | ROE | 10% | Altman Z Score | 3.43 | Piotroski Score | 8 |
| Current Ratio | 0.92 | Quick Ratio | 0.71 | Cash Ratio | 0.27 | Op. CF Ratio | 0.15 |
| Debt/Equity | 0.52 | Debt/Assets | 0.25 | Lt Debt/Equity | 0.38 | Lt Debt/Cap. | 0.32 |
| Intrst Cov. | — | Inventory Turnover | 3.79 | Asset Turnover | 0.34 | Receivables Turnover | 5.2 |
| Enterprise Value | $40.18B | P/E Ratio | 18.96 |
| Forward P/E | 16.34 | PEG Ratio | -4.62 |
| P/S Ratio | 3.35 | P/B Ratio | 2.31 |
| P/CF Ratio | 25.21 | P/FCF Ratio | 31.5 |
| EPS | $0.54 | EPS Growth 1Y | 20.5% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 14.45% | Gross Margin | 0.65% |
| Operating Margin | 0.22% | Profit Margin | 0.15% |
| ROE | 0.1% | ROA | 0.05% |
| ROCE | 0.09% | Current Ratio | 0.92 |
| Quick Ratio | 0.71 | Cash Ratio | 0.27 |
| Debt/Equity | 0.52 | Interest Coverage | — |
| Altman Z Score | 3.43 | Piotroski Score | 8 |
Haleon (HLN) valuation & financials
Haleon (HLN) has a market capitalization of $44.79B and trades at a price-to-earnings ratio of 19.0. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Haleon's revenue grew +14.5% over the last year.
Haleon's next earnings report is scheduled for March 4, 2027 before market open; analysts estimate EPS of $0.27. Check the earnings calendar to see all companies reporting this week.
Haleon (HLN) — frequently asked questions
When does Haleon (HLN) report earnings next?
Haleon is expected to report earnings on March 4, 2027 before market open. Analysts estimate EPS of $0.27.
What is Haleon's market cap?
Haleon (HLN) has a market capitalization of $44.79B.
What is HLN's P/E ratio?
Haleon trades at a price-to-earnings ratio of 19.0, with trailing twelve-month EPS of $0.54.
How fast is Haleon growing?
Haleon's revenue grew +14.5% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)